Clinical Trials Sponsored by BeiGene, Ltd.

Total 18562 results

Celgene

Terminated

A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States
Celgene

Completed

An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis

Colitis, Ulcerative

United States, Canada, Slovakia, Poland, Bulgaria, Hungary
Celgene

Completed

A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005)

Multiple Myeloma

United States, Spain, Austria, Greece, Netherlands, Sweden
Celgene

Withdrawn

A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Solid Tumor

United States
Celgene

Withdrawn

Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Neoplasms | Hematologic Diseases | Multiple Myeloma | Paraproteinemias | Blood Protein Disorders | Therapeutic Uses | Plasma Cells
Celgene

Completed

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects

Healthy Volunteers

United States
Celgene

Completed

Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Celgene

Completed

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma

Cancer | Lymphomas

United States
Celgene

Withdrawn

A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease

Crohn Disease

United States, Spain, Belgium, Denmark, Canada, Australia, Austria, United Kingdom, Netherlands, Italy, Korea, Republic of, Germany, Portugal, Croatia, Czechia, Greece, Hungary, Israel, Poland, Russian Federation, Serbia, Slovakia, ... and more
Celgene

Completed

A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Multiple Myeloma

Spain, United Kingdom, Switzerland, Australia, Israel, Italy, Poland, France, Belgium, Ireland, Austria, Germany, Ukraine, Greece, Sweden
Celgene

Completed

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Multiple Myeloma

United States, Canada
Celgene

Completed

Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
Celgene

Completed

To Document the Burden of Illness on the Quality of Life and the Impact on Healthcare Utilization in (Beta) β-thalassemia Subjects Who Are Transfusion Dependent (TD) and Non-transfusion Dependent (NTD) Receiving Standard of Care

Beta-Thalassemia

Greece, Italy, Lebanon, Thailand, Turkey
Celgene

Completed

Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment (MCL-004)

Lymphoma, Mantle-Cell

United States, Germany, Italy, United Kingdom
Celgene

Terminated

Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)

Multiple Myeloma

China
MediGene

Completed

EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients

Breast Neoplasms

Belgium, France, Poland, India, Romania, Ukraine
MediGene

Completed

A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases

Neoplasm Metastasis | Liver Cancer

Germany
Celgene

Not yet recruiting

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

Renal Impairment

United States
Celgene

Recruiting

A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, Israel, Spain, Denmark, France, Germany, Netherlands
Celgene

Recruiting

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid

United States, France, Canada
Celgene

Recruiting

Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)

Lymphoma Nonhodgkin

Japan
Celgene

Recruiting

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

United States
Celgene

Recruiting

A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma, Mantle-Cell

Spain, Italy, Germany, Austria, France, Greece, Netherlands
Celgene

Recruiting

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)

Multiple Myeloma

United States, France, Germany, Spain, United Kingdom, Italy
Celgene

Completed

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

United States
Celgene

Completed

A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients

Leukemia, Myeloid, Acute

Korea, Republic of, Australia
Celgene

Completed

A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

Neoplasms

United States, France, Italy, Poland, Spain, United Kingdom
Celgene

Active, not recruiting

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

Spain, Canada, United States
Celgene

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Eosinophilic Esophagitis

Australia, United States, Argentina, Austria, Belgium, Canada, Germany, Israel, Italy, Japan, Poland, Portugal, Spain, Switzerland, United Kingdom
Celgene

Completed

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States, Germany
Celgene

Terminated

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Lymphoma, Large B-Cell, Diffuse

United States, France, Canada, Italy
Celgene

Completed

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCENDWORLD)

Lymphoma, Non-Hodgkin

Italy, Switzerland, Austria, Belgium, France, Germany, Japan, Netherlands, Spain, United Kingdom, Finland
Celgene

Active, not recruiting

Connect® MM- The Multiple Myeloma Disease Registry

Multiple Myeloma

United States, Puerto Rico
Celgene

Completed

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

Lymphoma | Lymphoma, Large B-Cell, Diffuse | Glioblastoma | Multiple Myeloma | Primary Central Nervous System Lymphoma | Pleiotropic Pathway Modifier

United States, Spain, Belgium, France, Italy
Celgene

Completed

ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

Lymphoma, T-Cell, Peripheral

Japan
Celgene

Terminated

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease

Systemic Sclerosis | Scleroderma, Systemic | Systemic Scleroderma | Interstitial Lung Disease | Sclerosis, Systemic

United States, Spain, France, Australia, Italy, Switzerland, Germany, Poland, United Kingdom, Russian Federation
Celgene

Active, not recruiting

Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice

Multiple Myeloma

Austria
Celgene

Active, not recruiting

Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma (KarMMa-7)

Multiple Myeloma

United States, Spain
Celgene

Active, not recruiting

Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

Multiple Myeloma

United States, France, Spain, Germany, Greece
Celgene

Active, not recruiting

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Lymphoma

United States, France, Germany, Italy, Korea, Republic of, Taiwan
Celgene

Completed

Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants

Healthy Volunteers

United States
Celgene

Completed

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Primary Myelofibrosis | Anemia

United States, France, Italy, United Kingdom
Celgene

Completed

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)

Multiple Myeloma

United States
Celgene

Terminated

Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.

Beta Thalassemia Intermedia | Beta Thalassemia Major

France, United Kingdom, Italy, Greece
Celgene

Completed

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Belgium, Germany, Spain, Canada, Serbia, Colombia, Poland, Argentina, Brazil, Mexico, Hungary, France, Russian Federation, Italy
Celgene

Completed

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

United States, Austria, United Kingdom, Estonia, Denmark
Celgene

Active, not recruiting

A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma

Glioblastoma

Spain, United States, Denmark, Italy, Netherlands, Norway, Sweden
Celgene

Terminated

A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

Leukemia, Myeloid

United States, France, Belgium, Spain
Celgene

Completed

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Canada, Spain, United Kingdom, United States, France, Austria, Germany, Italy, Netherlands, Belgium, Portugal, Poland
Celgene

Terminated

A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

Carcinoma, Squamous Cell

United States

3

Subscribe